Literature DB >> 31960218

Toxocariasis of the Nervous System.

Maria Meliou1,2, Ioannis N Mavridis3, Efstratios-Stylianos Pyrgelis2,4, Eleni Agapiou2,5.   

Abstract

PURPOSE: Toxocariasis is a helminthozoonosis caused by the infection of a human host by the larva of Toxocara spp., predominately involving Toxocara canis and Toxocara cati, which are common nematodes in dogs and cats, respectively. Human transmission occurs through contact with animals or by consumption of food contaminated with parasite's eggs. The purpose of this article is to review the current knowledge regarding human neurotoxocariasis.
METHODS: We conducted a systematic review of the existing literature concerning toxocariasis of the nervous system.
RESULTS: Clinical spectrum of human toxocariasis varies widely from a subclinical course to significant organ morbidity. Clinical course depends on parasitic load, the migration route of the larvae and host response. Human neurotoxocariasis is a relatively rare entity yet associated with severe sequelae. Manifestations include meningitis (usually eosinophilic), encephalitis, myelitis, cerebellar vasculitis, space-occupying lesion, behavioral abnormalities, and optic neuritis. Even though valid diagnostic criteria are lacking, neurotoxocariasis should be suspected in patients with neurologic symptoms and cerebrospinal fluid (CSF) pleocytosis with eosinophilia, positive serology for anti-Toxocara antibodies, in serum and/or CSF, sterile CSF and clinical improvement after antihelminthic treatment. Neurotoxocariasis is treated by benzimidazole components, most frequently albendazole, corticosteroids, or diethylcarbamazine.
CONCLUSION: Parasite larvae migrate through tissues and are able to reach the nervous system causing neurotoxocariasis. Its clinical spectrum varies and includes myelitis, meningoencephalitis, brain abscess, and vasculitis. Neurotoxocariasis should always be suspected in patients with neurologic symptoms accompanied by eosinophilia in blood and/or CSF. Early diagnosis and treatment could prevent long-term neurologic impairment.

Entities:  

Keywords:  Albendazole; Encephalitis; Meningitis; Nematode; Toxocariasis

Mesh:

Substances:

Year:  2020        PMID: 31960218     DOI: 10.2478/s11686-019-00166-1

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  6 in total

Review 1.  Neuroimmunology of Common Parasitic Infections in Africa.

Authors:  Richard Idro; Rodney Ogwang; Antonio Barragan; Joseph Valentino Raimondo; Willias Masocha
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

2.  Toxocara canis infection manifesting as cerebral vasculitis: a case report.

Authors:  Simela Chatzikonstantinou; Konstantinos Polymeropoulos; Alexia Stavrati; Galaktion Konstantinidis; Dimitrios Kazis
Journal:  Neurol Sci       Date:  2022-04-04       Impact factor: 3.830

3.  Toxocariasis affecting brain stem and skull base.

Authors:  Manuel Gomez Serrano; Rafael Jimenez Rodriguez-Madridejos; Salome Merino Menendez; Diana Maria Hernanperez Hidalgo; Jesus Gimeno Hernández; Maria Cruz Iglesias Moreno
Journal:  BMC Infect Dis       Date:  2021-12-11       Impact factor: 3.090

Review 4.  Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases.

Authors:  Fabian Lötscher; Roxana Pop; Pascal Seitz; Mike Recher; Luca Seitz
Journal:  Curr Rheumatol Rep       Date:  2022-08-03       Impact factor: 4.686

5.  High Seroprevalence of Toxocara Infection among Mentally Retarded Patients in Hormozgan Province, Southern Iran.

Authors:  Mostafa Omidian; Mariye Diyaleh; Ali Pouryousef; Habibollah Turki; Fattaneh Mikaeili; Bahador Sarkari
Journal:  J Trop Med       Date:  2021-05-06

6.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.